Severe hepatotoxicity secondary to nintedanib
Marta Librero Jiménez1, Clara Heredia Carrasco1, María Del Carmen Fernández Cano1
1Aparato Digestivo, Hospital Universitario Virgen de las Nieves, España.
Nintedanib, a treatment for idiopathic pulmonary fibrosis, can cause severe liver damage and jaundice. This report details the first documented cases of this serious adverse reaction.
Area of Science:
- Pharmacology
- Hepatology
- Pulmonology
Background:
- Nintedanib is a tyrosine kinase inhibitor approved for treating idiopathic pulmonary fibrosis (IPF).
- Idiopathic pulmonary fibrosis is a progressive, fatal lung disease.
- Liver toxicity is a known, but typically mild, side effect of nintedanib.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Hepatic Drug Excretion: Influencing Factors
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists


